Saturday, 31st January 2026, has approved the Standalone and Consolidated unaudited. financial results, for…
As filed · Outcome of Board Meeting
EarningsMajormateriality 77 out of 100
What happened
FactSaturday, 31st January 2026, has approved the Standalone and Consolidated unaudited. financial results, for the quarter and nine months ended 31st December, 2025. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedEarlierQ4 FY25
Vegetables: Robust growth of 60% in value and 76% in quantity, driven by higher market penetration and new product launches.
NowQ4 FY25
Maize: Strong 47% YoY growth on the back of improved product acceptance.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved -21.67%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- This year, you will see the significant improvement by the end of this quarter, you will realize what kind of (management committed by Q4 FY26)
- Within next three years' time, Nath would be either similar to Kaveri or better to Kaveri in hybrid segment. (management committed by FY27)
Evidence
- Nath Bio-Genes (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q4 FY25
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%